As monotherapy with GLP-1 RAs or tirzepatide increasingly achieves double-digit weight loss, combination pharmacotherapy is emerging as a promising frontier in obesity treatment. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.